688363.SH
华熙生物
SSE · Basic Materials · Chemicals - Specialty · CN
CNY 35.33
−2.89%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.0B | 4.2B | 5.4B | 6.1B | 6.4B |
| Cost of Revenue | 1.2B | 1.2B | 1.4B | 1.6B | 1.5B |
| Gross Profit | 2.7B | 3.0B | 4.0B | 4.5B | 4.9B |
| Operating Expenses | |||||
| R&D Expense | 453.0M | 472.1M | 466.2M | 446.3M | 388.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 524.6M | 541.7M | 658.4M | 492.2M | 392.9M |
| Selling & Marketing Expense | 1.4B | 1.5B | 2.5B | 2.8B | 3.0B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.4B | 2.6B | 3.6B | 3.8B | 3.9B |
| Cost and Expenses | 3.6B | 3.8B | 5.0B | 5.4B | 5.3B |
| Operating Income (EBIT) | 270.2M | 333.1M | 215.9M | 708.4M | 1.1B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 268.5M | 333.8M | 213.4M | 701.7M | 1.1B |
| Income Tax Expense | 13.4M | 42.7M | 45.0M | 119.0M | 174.7M |
| Bottom Line | |||||
| Net Income | 254.8M | 292.1M | 174.3M | 592.6M | 970.9M |
| Earnings from Cont. Ops | 255.0M | 291.1M | 168.4M | 582.7M | 961.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 254.8M | 292.1M | 174.3M | 592.6M | 970.9M |
| Per Share | |||||
| Basic EPS | CN¥0.54 | CN¥0.61 | CN¥0.36 | CN¥1.23 | CN¥2.02 |
| Diluted EPS | CN¥0.54 | CN¥0.61 | CN¥0.36 | CN¥1.23 | CN¥2.01 |
| Revenue Per Share | CN¥8.55 | CN¥8.77 | CN¥11.09 | CN¥12.61 | CN¥13.23 |
| Shares | |||||
| Basic Shares Outstanding | 461.8M | 478.8M | 484.1M | 481.8M | 480.7M |
| Diluted Shares Outstanding | 461.8M | 478.8M | 484.1M | 481.8M | 480.7M |
| Profitability Metrics | |||||
| EBITDA | — | 676.5M | 485.3M | 941.4M | 1.3B |
| D&A | — | 343.4M | 269.4M | 233.0M | 177.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026